Financial Results - For the FYE March 2016 -
1. Overview for FYE March 2016
2. Initiatives to Address Issues
FYE March 2017 Guidance
FYE March 2017 will Focus on Gaining Secure Foothold for Continued Growth
Food: Health-oriented Food Market is Expanding - Promote Our Unique Value to Increase Market Share
Food: Promote Structural Reforms
Pharma: Offset NHI Drug Price Revisions to Achieve Further Growth
Pharma: Focus on Our Expertise to Develop New Drugs
Food: Realize Solid Growth in Overseas Markets
Pharma: Expand overseas business into core business that rivals domestic operations
Strengthen Corporate Governance and Quality Assurance/Control System
3. Meiji's Approach to Realizing Sustainable Growth
100 YEARS YOUNG
Offset 9.2 billion yen in incomes losses due to NHI price revisions to continue growth.
Domestic ethical pharmaceuticals
Maintaining strong presence with No. 2 share for both systemic antibacterial drugs and antidepressant drugs
Release new drugs in areas of strength for both brand-name and generic markets.
-Sycrest, antipsychotic drug, is scheduled for release in May.
-Anti-allergy drug, COPD drugs
-Enhance generic lineup
Promote those new drugs together with existing products and maximize the first year sales.
Agrochemical and veterinary drugs
Accelerate selection and concentration and improve profitability – break-even
Continue structural reforms to establish a stable profit structure